STOKNMSHealthcare·Biotechnology#99 in industry

Stoke Therapeutics, Inc.

Reports in 16d· 2026-05-12

+14.2% · 90d

$33.70

-0.33 (-0.97%)

News

(3)

April 2026

Apr 22, 20265 days agoARSHealthcare

Insufficient Filing Content to Draft Headline

STOKStoke Therapeutics, Inc.

I am ready to act as your expert financial analyst and educator. I understand the specific structural requirements, the depth of explanation needed for every section, and the critical importance of maintaining accuracy regarding dates, figures, and executive commentary. However, the content of the

Read summaryView on SEC EDGAR

Apr 22, 20265 days agoDEF 14AHealthcare

Stoke files annual proxy statement detailing 2026 stockholder governance proposals

STOKStoke Therapeutics, Inc.

# ✉️ What This Document Is This document is Stoke Therapeutics, Inc.'s Proxy Statement, a required legal filing that explains the business and governance matters for the 2026 Annual Meeting of Stockholders. It is essentially a roadmap for your rights as a shareholder, detailing the key decisions the

Read summaryView on SEC EDGAR

Apr 7, 20262 weeks ago8-KHealthcare

Stoke Therapeutics, Inc. — 8-K Filing

STOKStoke Therapeutics, Inc.

# 🧾 What This Document Is This is an **8-K filing**, a report companies submit to the SEC to announce major, shareholder-impacting news. In this case, Stoke Therapeutics is formally announcing the appointment of a new expert, **Clare Kahn, Ph.D.,** to its Board of Directors. It’s a standard but imp

Read summaryView on SEC EDGAR

Key Data

Market Cap$1.99B

Open$33.96

Prev Close$34.03

Day Range$33.63 – $34.93

52W Range$8.30 – $40.22

Volume122,513

P/E (TTM)—

EPS$-0.12

Dividend Yield—

Beta1.22

Profit Margin-3.73%

Revenue Growth-93.80%

Price Target$45.10(+33.8%)

Next Earnings2026-05-12(16d)

Analyst Ratings

Strong Buy12 analysts

Buy 12Hold 0Sell 0

About

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Healthcare · Biotechnology

170 employees

www.stoketherapeutics.com